

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JCE15 U.S. PTO
09/728173
12/01/00

Examiner : Not Yet Assigned
Group Art Unit: Not Yet Assigned
Applicants : Keisuke Kuida et al.,
Serial No. : Not Yet Assigned
Filed : Herewith
For : CASPASE-9 DEFICIENT ANIMALS AND THE USE
THEREOF

Cambridge, Massachusetts
December 1, 2000


Hon. Assistant Commissioner
For Patents
Washington, D.C. 20231

STATEMENT TO VERIFY CONTENT OF COMPUTER
READABLE FORM SUBMISSION UNDER 37 C.F.R. 1.821(f)

Sir:

I hereby state that the content of the paper and the computer readable copy of
the Sequence Listing, submitted herewith in accordance with 37 C.F.R. 1.821 (c) and
(e), respectively, are the same.

Respectfully submitted,


Andrew S. Marks (33,259)
Attorney for Applicants

c/o Vertex Pharmaceuticals Inc.
130 Waverly Street
Cambridge, MA 02139-4242
Tel.: (617) 577-6692
Fax.: (617) 577-6680

SEQUENCE LISTING

<110> Kuida, Keisuke (US only)
Flavell, Richard A. (US only)
5 Vertex Pharmaceuticals, Inc.
Yale University

<120> CASPASE-9 DEFICIENT ANIMALS AND THE USE THEREOF

10 <130> Caspase-9 Knockout

<140>
<141>

15 <150> US 60/087,711
<151> 1998-06-02

<160> 7

20 <170> PatentIn Ver. 2.0

<210> 1
<211> 22
<212> DNA

25 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
oligonucleotide primer

30

<400> 1
atggacgaag cggatcggcg gc 22

<210> 2

35 <211> 21
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide primer

<400> 2

5 ttatgatgtt ttaaagaaaa g

21

<210> 3

<211> 24

<212> DNA

10 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide primer

15

<400> 3

gccatggacg aagcggatcg gcgg

24

<210> 4

20 <211> 24

<212> DNA

<213> Artificial Sequence

<220>

25 <223> Description of Artificial Sequence:
oligonucleotide primer

<400> 4

30 ggctctggatg aagaagagct tggg

24

<210> 5

<211> 24

<212> DNA

<213> Artificial Sequence

35

<220>

<223> Description of Artificial Sequence:
oligonucleotide primer

<400> 5
gggaagatgg atgcaaaagc tcga

24

<210> 6
5 <211> 24
<212> DNA
<213> Artificial Sequence

<220>
10 <223> Description of Artificial Sequence:
oligonucleotide primer

<400> 6
atggtgcaa ttcttctctg taag

24

15 <210> 7
<211> 5
<212> PRT
<213> mammalian

20 <220>
<221> UNSURE
<222> (4)
<223> X is arginine or glycine

25 <220>
<221> DOMAIN
<222> (1)..(5)
<223> Pentapeptide motif common to all known caspases

30 <400> 7
Gln Ala Cys Xaa Gly
1 5